Extension study to evaluate the long term safety and efficacy of Bimatoprost ophthalmic solution 0.03% w/v compared with timolol 0.5% w/v ophthalmic solution for up to four years of dosing.
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Bimatoprost (Primary) ; Timolol
- Indications Glaucoma; Ocular hypertension
- Focus Therapeutic Use
- 10 May 2017 New trial record